Milan - Delayed Quote EUR

Sanofi (1SAN.MI)

90.17

-3.16

(-3.39%)

At close: May 12 at 5:35:13 PM GMT+2

Bristol-Myers Squibb, Sanofi Enter $700 Million Settlement With Hawaii in Plavix Lawsuit

Bristol-Myers Squibb (BMY) and three US-based units of Sanofi (SNY) have reached a settlement for $7

PREMIUM
MT Newswires 12 hours ago

SNY

CELG-RT
Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

(Bloomberg) -- President Donald Trump said he plans to order a cut in US prescription drug costs to bring them in line with other countries, spurring a drop in pharmaceutical shares worldwide.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?NYC Warns of 17% Drop in Foreign Tourists Due to Trump PoliciesLA Mayor Credits Trum

Bloomberg 14 hours ago

AZN

AZNCF

BERZ
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

(Bloomberg) -- Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US prescription drug costs to bring them in line with other countries, prompting concern that profits will take a hit.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?Is Trump’s Plan to R

Bloomberg 17 hours ago

C

TAK

TKPHF
Drug companies to pay Hawaii $700 million to settle Plavix blood thinner lawsuit

Pharmaceutical companies have agreed to pay Hawaii $700 million to settle its lawsuit over the efficacy and safety of the blood thinner Plavix, the state attorney general's office announced Friday. A court ruling last year ordered Bristol Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi to pay a combined $916 million. “Plavix has helped millions of people with cardiovascular disease around the world for nearly 30 years and it continues to be endorsed as a first-line therapy by leading treatment guidelines across the globe,” the statement added.

Associated Press Finance 2 days ago

SNY

CELG-RT
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.

Zacks 3 days ago

NVAX

SNY

ADPT
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

On Thursday, Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million. Higher product sales for the first quarter of 2025 were primarily due to $603 million of revenue recognized with the termination of two Advance Purchase Agreements (APA) and related to cash received in prior years. $45 million of Licensing, Royalties, & Other Revenue in the first quarter of 2025 was higher than the prior year due

Benzinga 4 days ago

NVAX

SNY
Sanofi exec tells biotechs not to scrimp on clinical trial design

It is vital for biotech companies to run the right clinical trial and not cut costs with trial design or patient recruitment, the executive said.

Clinical Trials Arena 4 days ago

SNY
Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S. regulators saying that it sees a pathway to resolving issues with the FDA, sending shares up nearly 19% in early trading. The vaccine maker said it believes commitments to run new trials would be after it receives approval for the shot. The vaccine's prospects were thrown into doubt after the U.S. Food and Drug Administration missed its April 1 target to approve the shot.

Reuters 4 days ago

NVAX

SNY
Novavax to Report First-Quarter Earnings: Is a Beat in Store?

On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates.

Zacks 7 days ago

NVAX

SNY
European Firms Fare Better Than Feared Through Early Trade Pain

(Bloomberg) -- European firms are reporting earnings significantly ahead of expectations, allowing for some relief in the market, but tariffs and the uncertain path of economic growth continue to cloud the outlook.Most Read from BloombergThe Battle Over the Fate of Detroit’s Renaissance CenterNYC Real Estate Industry Asks Judge to Block New Broker Fee LawNJ Transit Strike Would Be ‘Disaster’ for Region, Sherrill SaysIceland Plans for a More Volcanic FutureNJ Transit Urges Commuters to Work Remot

Bloomberg 7 days ago

SNY

SNYNF

SCGLF
Sanofi: Information concerning the total number of voting rights and shares - March 2025

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

GlobeNewswire 10 days ago

SNY

SNYNF
Sanofi (ENXTPA:SAN) Announces €4 Per Share Dividend And New Compensation Committee Chair

Sanofi (ENXTPA:SAN) saw a 2.85% increase in its share price last week, coinciding with notable company updates. The pharmaceutical giant announced a dividend increase to €3.92 per share during its Annual General Meeting, likely reinforcing investor confidence. Additionally, Clotilde Delbos' appointment as Chairwoman of the Compensation Committee underscores a strategic personnel change. While the market also rose by 2.7%, Sanofi's earnings boost and dividend announcement may have added...

Simply Wall St. 11 days ago

SNY

SNYNF
Sanofi (SNY, Financials) Completes Opella Deal, Creates Consumer Health Leader

Sanofi retains 48.2% ownership and shifts focus to core biopharma business

GuruFocus.com 11 days ago

SNY
Press Release: Annual General Meeting of April 30, 2025

Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders

GlobeNewswire 12 days ago

SNY

SNYNF
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake. Bpifrance will own a 1.8% stake in Opella and will join the Board. The tran

GlobeNewswire 12 days ago

SNY

SNYNF
Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ...

Swedish Orphan Biovitrum AB (BIOVF) reports robust revenue growth driven by haematology, while facing challenges in immunology and strategic market expansions.

GuruFocus.com 12 days ago

SWOBY

SNY
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.

Zacks 13 days ago

REGN

SNY

BAYN.DE
Regeneron's first-quarter results miss on lower Eylea demand

(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied approval for a more convenient version of the eye therapy. Shares of Regeneron were down nearly 8%. Regeneron has been looking to switch patients to a higher-dose version of the drug, branded as Eylea HD, to stymie the loss in market share to cheaper versions and rivals.

Reuters 13 days ago

REGN

SNY
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race Paris, April 29, 2025. Sanofi is proud to unveil an exciting new chapter in its mission to fight meningitis, as it expands its partnership with McLaren Racing for a powerful activation alongside United Autosports, the official racing partner of McLaren Automotive. This unique collaboration will see the Meningitis Flag — a powerful symbol of the global fight ag

GlobeNewswire 13 days ago

SNY

SNYNF
Private Equity Firms Target Defense Assets Once Seen as Toxic

(Bloomberg) -- Private equity firms are scouring for investment opportunities in European defense, chasing the once shunned sector in an effort to benefit from a historic switch to military expansion in the region.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryNYC’s Congestion Toll Raised $159 Million in the First QuarterUS Cricket Deepens Bet on Texas With HQ Shift From CaliforniaLos Angel

Bloomberg 14 days ago

IVCGF

SNY

SNYNF

Performance Overview

Return	1SAN.MI	CAC 40 (^FCHI)
YTD	+1.04%	+6.36%
1-Year	+3.92%	-4.49%
3-Year	+4.43%	+26.49%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi (1SAN.MI)

Bristol-Myers Squibb, Sanofi Enter $700 Million Settlement With Hawaii in Plavix Lawsuit

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

Drug companies to pay Hawaii $700 million to settle Plavix blood thinner lawsuit

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

Sanofi exec tells biotechs not to scrimp on clinical trial design

Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears

Novavax to Report First-Quarter Earnings: Is a Beat in Store?

European Firms Fare Better Than Feared Through Early Trade Pain

Sanofi: Information concerning the total number of voting rights and shares - March 2025

Sanofi (ENXTPA:SAN) Announces €4 Per Share Dividend And New Compensation Committee Chair

Sanofi (SNY, Financials) Completes Opella Deal, Creates Consumer Health Leader

Press Release: Annual General Meeting of April 30, 2025

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ...

Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

Regeneron's first-quarter results miss on lower Eylea demand

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

Private Equity Firms Target Defense Assets Once Seen as Toxic

Performance Overview